Cost-effectiveness analysis (CEA) of seven treatment regimens in metastatic hormonesensitive prostate cancer (mHSPC): A public payer perspective using network metaanalysis

被引：0
|
作者：
Kohli, Manish
Dougherty, Maura
Cutshall, Zachary
Beckstead, Rylee
Kohli, Rhea
Haaland, Benjamin
Nelson, Richard
Yoo, Minkyoung
机构：
[1] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[2] Univ Utah, Salt Lake City, UT USA
[3] Case Western Reserve Univ, Cleveland, OH 44106 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5081
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Cost-Effectiveness Analysis of Systemic Therapy for Intensification of Treatment in Metastatic Hormone-Sensitive Prostate Cancer in India
    Nidhi Gupta
    Dharna Gupta
    Kiran Gopal Vaska
    Shankar Prinja
    Applied Health Economics and Health Policy, 2024, 22 : 415 - 426
  • [22] Cost-Effectiveness Analysis of Systemic Therapy for Intensification of Treatment in Metastatic Hormone-Sensitive Prostate Cancer in India
    Gupta, Nidhi
    Gupta, Dharna
    Vaska, Kiran Gopal
    Prinja, Shankar
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2024, 22 (03) : 415 - 426
  • [23] Cost-effectiveness analysis (CEA) of bevacizumab (Bev) in first- and second-line treatment of metastatic colorectal cancer (mCRC)
    Goldstein, Daniel A.
    Chen, Qiushi
    Howard, David H.
    Lipscomb, Joseph
    Ayer, Turgay
    El-Rayes, Bassel F.
    Flowers, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [24] Multi-arm Cost-Effectiveness Analysis (CEA) comparing different durations of adjuvant trastuzumab in early breast cancer, from the English NHS payer perspective
    Clarke, Caroline S.
    Hunter, Rachael M.
    Shemilt, Ian
    Serra-Sastre, Victoria
    PLOS ONE, 2017, 12 (03):
  • [25] COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF MOMETASONE FUROATE AS MAINTENANCE TREATMENT IN PATIENTS WITH MILD TO MODERATE ASTHMA FROM THE PUBLIC PAYER PERSPECTIVE IN BRAZIL
    Fernandes, R. A.
    Takemoto, M. L.
    Cukier, F. N.
    Guerra, F. C.
    Passos, R. B.
    VALUE IN HEALTH, 2010, 13 (07) : A323 - A323
  • [26] COST-EFFECTIVENESS OF SYSTEMIC TREATMENT INTENSIFICATION IN MEN WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
    Sathianathen, Niranjan
    Lawrentschuk, Nathan
    Azad, Arun
    Konety, Badrinath
    Murphy, Declan
    JOURNAL OF UROLOGY, 2023, 209 : E492 - E492
  • [27] Cost-effectiveness analysis of bicalutamide (Casodex™) for adjuvant treatment of early prostate cancer
    Moeremans, K
    Caekelbergh, K
    Annemans, L
    VALUE IN HEALTH, 2004, 7 (04) : 472 - 481
  • [28] Cost-effectiveness analysis of triptorelin versus leuprolide in the treatment of advanced prostate cancer
    Ravasio, Roberto
    GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2016, 3 (03) : 150 - 154
  • [29] Cost-Effectiveness Analysis for Therapy Sequence in Advanced Cancer: A Microsimulation Approach with Application to Metastatic Prostate Cancer
    Handorf, Elizabeth A.
    Beck, J. Robert
    Correa, Andres
    Ramamurthy, Chethan
    Geynisman, Daniel M.
    MEDICAL DECISION MAKING, 2023, 43 (7-8) : 949 - 960
  • [30] Cost-effectiveness analysis of nivolumab-chemotherapy as first-line therapy for locally advanced/metastatic gastric cancer: a United States payer perspective
    Marupuru, Srujitha
    Arku, Daniel
    Axon, David R.
    Villa-Zapata, Lorenzo
    Yaghoubi, Mohsen
    Slack, Marion K.
    Warholak, Terri
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2023, 23 (07) : 831 - 841
12345